Introduction
The treatment of chronic myeloid leukemia (CML) has been revolutionized by the introduction of molecularly directed therapy that specifically targets and inhibits the tyrosine kinase (TK) activity of the BCR-ABL protein. Imatinib mesylate (IM) is extremely effective in suppressing Ph+ cells resulting in significant responses in CML. IM has resulted in not only achieving complete hematological remissions (CHR), but also results in complete cytogenetic responses (CCR) and molecular remission. [1] [2] [3] [4] It is, however, still unclear if IM achieves cure and hematopoietic stem cell transplantation (SCT) remains the only modality with documented curative results, achieving 50-80% long term survivals for patients in CP, and progressively lower results for patients transplanted beyond first CP. 5, 6 While most data regarding the use of IM for CML derives from studies in adult patients this treatment strategy has now been expanded to include children with Ph+ CML. 7, 8 However, little information is available regarding response, outcome and toxicity of IM in children. At our institution we have used this adult-based strategy for children keeping SCT as the ultimate treatment of choice when a suitable donor source is available. Mainly descriptive statistics were generated and relapse free survival (RFS) for the patients was calculated using the method of Kaplan and Meier. Relapse was considered when patients reverted to at least cytogenetic positivity after having achieved major molecular responses (MMR; > 3 log reduction in BCR-ABL transcript).
Results
Twelve patients were diagnosed with CML, constituting 2% of all pediatric leukemias seen at our institution during that time. The clinical characteristics are shown in Table 1 .
All patients in CP started therapy with Hydroxyurea (HU); in eight patients IM was added within one week, following cytogenetic confirmation, and was continued for a median of Imatinib was reasonably well tolerated. Hematological toxicity was more frequent and severe during the first three months of therapy (Table 3) . Non-hematological toxicities were generally mild and transient, except for joint pains. Five patients developed significantly severe lower extremity and joint pain, resulting in major limitation of movement and altered normal function. IM dosage had to be reduced in all patients and discontinued in three. While IM could be restarted at lower doses and gradually increased to full dose in most patients, one patient (#11) could not tolerate it. Only one of these patients had mild to moderate lower extremity edema associated with the joint pain. Cardiac dysfunction has not been observed in any of our patients to date as determined by routine echocardiographic evaluations.
Discussion
CML is a rare diagnosis in children. This is reflected in the paucity of data relating to pediatric patients with CML in the international literature. While pediatric studies are being conducted, treatment of children with CML is primarily based on the experience derived from adult studies.
IM is considered the primary first line treatment for CML in adult patients. 5, 9 Phase I/II studies of IM in children confirmed its safety and efficacy, 7, 10 and although no phase III clinical trials in children have been reported, the benefit seen in adults provided sufficient evidence to warrant use in children. However, the therapeutic aim in children differs from that in adults, with definitive cures being sought in children and delays in progression in adults. Evident data exist confirming that IM may not be curative for most patients with CML even after achieving undetectable BCR-ABL levels. Quiescent leukemia stem cells are believed resistant to IM and repopulate the bone marrow if IM is discontinued. 11 Current recommendation for adult patients on IM as first line therapy, without SCT, is to continue the treatment indefinitely. Whether this should apply to the pediatric patient as well remains to be seen. Although most of our patients on IM achieved molecular responses, all still have detectable BCR-ABL. This would confirm the supposition that IM, at least over the relatively short term duration used in our patients, is not curative. In contrast, at least half of the transplanted patients have achieved undetectable BCR-ABL levels and actual cures can be expected for them.
Thus, SCT remains possibly the only curative option for patients with CML. However, the 5-year survival is significantly better for pediatric patients in CP1 following MSD SCT than with alternative donors. 8 Based on such data our own practice has been to offer MSD SCT to patients with CML in CP1 and to continue IM for the remaining until availability of a suitable donor or further data is generated that would allow changes in practice. A recent survey of pediatric oncologists and transplanters also highlights the non-uniformity in CML treatment for pediatric patients. 12 However, 63% of the respondents continue to recommend MSD-SCT in first CP after using IM upfront.
As has been reported previously, 13 and is evident from our data, 14,15 Non-hematological toxicity, however, was quite different when compared to adults. Fluid retention and edema, commonly encountered in adult patients, was only noted in one of our patients. 15-20% of adult patients may suffer from mild joint pains. 16 Arthralgia was probably the most debilitating toxicity in our patients, forcing therapy alterations. Interestingly, this toxicity was mostly transient and after dose reduction and symptom resolution, most patients could tolerate full dose. Only minor hepatic dysfunction was noted and none of the patients suffered cardiac abnormalities. Until such time as more long-term data are available our strategy seems to hold validity.
All patients with Ph+ CML should be treated with IM. Those with a suitably matched family donor should undergo SCT. Patients without a family donor may continue on IM keeping in mind that this may likely not achieve curative results and at present the duration of therapy is not determined.
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The authors declare no competing financial interests. Table 2 . Treatment provided and outcome for the patients with CML. to combine with the reverse primer in the ABL exon a4. The fluorescent hybridization probe pair is located in the ABL exon a3. The location of primers and hybridization probes also allows the amplification and detection of the b2a2 and b3a2 fusion transcripts. The amount of fluorescence resulting from the two probes is proportional to the amount of PCR product. The method uses 5 standards of 10 -1 to10 -4 dilution of k562 RNA in normal RNA which is diluted fresh and undergoes RT in each run. The limit of detection is 1/10000
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and any result <1/10000 undergoes nested PCR before being considered negative. The sensitivity of the nested PCR is expected to be at the 10 -5 -10 -6 level.
